With the advent of human induced pluripotent stem cell (hiPSC) technology, it is now possible to derive patient-specific cell lines that are of great potential in both basic research and the development of new therapeutics for human diseases. Not only do hiPSCs offer unprecedented opportunities to study cellular differentiation and model human diseases, but the differentiated cell types obtained from iPSCs may become therapeutics themselves. These cells can also be used in the screening of therapeutics and in toxicology assays for potential liabilities of therapeutic agents. The remarkable achievement of transcription factor reprogramming to generate iPSCs was recognized by the award of the Nobel Prize in Medicine to Shinya Yamanaka in 2012, just 6 years after the first publication of reprogramming methods to generate hiPSCs (Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., and Yamanaka, S. (2007) Cell 131, 861-872). This minireview series highlights both the promises and challenges of using iPSC technology for disease modeling, drug screening, and the development of stem cell therapeutics.
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The minireviews in the series cover topics including the use of differentiated cells derived from induced pluripotent stem cells (iPSCs), 2 such as heart cells (cardiomyocytes), in toxicity assays with new or existing therapeutics and the use of iPSCderived cells for drug screening both for new drug candidates and repurposing of existing drugs. Three minireviews focus on the problems of using iPSC-derived cells in regenerative medicine: immune issues for autologous therapy will be considered in one minireview; the issue of genetic instability in iPSCs and iPSC-derived cells will be considered in the second; and preclinical studies with iPSCs and iPSC-derived cells will be discussed. Finally, molecular techniques for correction of gene mutations in iPSCs will be covered.
In the first minireview of the series, Kyle Kolaja discusses "stem cells and stem cell-derived tissues and their use in safety assessment" (1) . Toxicology research has traditionally relied on animal studies to provide preclinical safety assessment of various therapeutic agents under development. With the advent of stem cell and iPSC technology, these cells and their differentiated counterparts provide an attractive alternative to animal testing. In this article, Kolaja discusses the state of the art for a number of stem cell-derived tissues and their application in toxicology research. Kolaja proposes that future toxicology studies will integrate genetic diversity in screening as well as complex in vitro derived organoids, three-dimensional models of human organs.
In the second minireview, Sandra J. Engle and Fabien Vincent discuss "small molecule screening in human induced pluripotent stem cell-derived terminal cell types" (2) . Because hiPSCs offer a means to generate genetically defined cellular disease models, there is tremendous potential in using hiPSC-derived cell types for drug screening. Engle and Vincent discuss small molecule high throughput screening in hiPSC-derived cells and how such screens are beginning to influence the drug discovery process in both academic and industrial settings. However, the authors note that numerous challenges must be overcome for such screening efforts to yield new therapeutic agents. Nonetheless, hiPSC technology may have a profound impact on just how drug discovery is conducted in the future.
Next, Zachary S. Scheiner, Sohel Talib, and Ellen G. Feigal discuss "the potential for immunogenicity of autologous induced pluripotent stem cell-derived therapies" (3). Although hiPSC technology offers the promise of immune-matched cellular therapies for a wide range of diseases and injuries, numerous challenges also must be overcome before this promise is realized in the clinic. For example, it is widely held that autologous iPSCs will be immune-privileged; however, recent studies have tested the immunogenicity of hiPSCs, and varying results have been obtained. Thus, the development of strategies to avoid an immune response is of paramount importance prior to initiation of human clinical trials with stem cellderived cell types. The authors review recent studies on autologous iPSC immunogenicity, its potential causes, and approaches for assessment and mitigation.
In the next minireview focusing on problems using hiPSCs as therapeutics, Suzanne E. Peterson and Jeanne F. Loring discuss "genomic instability in pluripotent stem cells: implications for clinical applications" (4). Human stem cells and iPSCs have been shown to acquire genomic changes as they proliferate and differentiate. For the successful use of hiPSCs in regenerative medicine, it is crucial to understand whether such genomic changes will be deleterious or simply innocuous. For example, tumor-causing mutations will need to be avoided, so necessary precautions will need to be taken to avoid adverse consequences in regenerative medicine. This minireview summa-rizes our current knowledge and provides a prospective view for the field.
Next, John Harding and Oleg Mirochnitchenko discuss "preclinical studies for induced pluripotent stem cell-based therapeutics" (5) . The authors provide a review of preclinical applications, including the use of iPSCs to treat diseases of the liver, nervous system, eye, and heart and metabolic conditions such as diabetes. Although these studies illustrate the significant potential of iPSC-derived cells, they also identify numerous challenges that must be addressed before moving to clinical trials. These include rigorous quality control and efficient production of required cell populations; improvement of cell survival and engraftment; development of technologies to monitor transplanted cell behavior for extended periods of time; and solving problems related to immune rejection, genetic instability, and tumorigenicity. Testing the efficacy of iPSC-based therapies requires further improvement of animal models precisely recapitulating human disease conditions. Finally, Mo Li, Keiichiro Suzuki, Na Young Kim, Guang-Hui Liu, and Juan Carlos Izpisua Belmonte discuss gene editing in iPSCs in their article entitled "A Cut above the Rest: Targeted Genome Editing Technologies in Human Pluripotent Stem Cells" (6) . Genome editing techniques offer the possibility to correct disease-causing mutations and transform patient cells into normal counterparts for regenerative medicine. Izpisua Belmonte and colleagues provide an overview of the various genome editing tools in current use, including zinc finger nucleases (ZFNs), tran-scription activator-like effector nucleases (TALENs), clustered regularly interspaced short palindromic repeat (CRISPR)/CAS9 RNA-guided nucleases, and helper-dependent adenoviral vectors (HDAdVs). The authors discuss the features and limitations of these technologies, as well as how genome editing will benefit both basic research and therapies. These breakthroughs in gene engineering techniques have further enhanced the potential of iPSC-based screening and therapy as discussed in the minireview. The editors hope that this series will be a useful resource for scientists in the iPSC field and those who wish to enter this exciting area of research.
